Abbott is launching the EnSite X cardiac electrophysiology mapping system in Europe and Australia after it received a CE mark and Australian Therapeutic Goods Administration approval, the company announced on 2 November.
EnSite X is a new cardiac mapping system for cardiac ablation built on the company’s existing EnSite mapping system with improvements created in response to physician feedback. (Also see "